Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CC-486 and Pembrolizumab in Previously Treated Advanced NSCLC
NCT02546986Phase 2Terminated
- Sponsor
- Celgene Corporation
- Start
- Oct 2015
- Primary completion
- Apr 2017
- Modality
- Small Molecules
- Countries
- 6
01
Overview
A Phase 2 trial of CC-486 in non-small cell lung cancer (NSCLC), sponsored by Celgene Corporation. Started Oct 2015; status: terminated.
02
Drugs
CC-486
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02546986.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02546986.